Pfizer and Novo Nordisk’s fight for obesity drug developer Metsera ratcheted up on Tuesday, as both companies submitted sweetened bids, with Metsera saying Novo’s $10 billion offer is superior. The dramatic...
Cipla to fully acquire Inzpera Healthscience
Drug maker Cipla on Monday said it has inked a pact to fully acquire Inzpera Healthscience for around Rs 111 crore. The drug maker has entered into definitive agreements to acquire 100 per cent stake in Inzpera...
Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up
Novo Nordisk and Pfizer have revised their bids for Metsera, the obesity drug developer said on Tuesday. Novo’s revised offer brings the deal value to about $10 billion, while Pfizer is now willing to shell out $8...
Novartis to acquire Avidity Biosciences for about $12 billion
Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash, as the company looks to bolster its portfolio of treatments for rare muscle disorders. As...
CCI clears Torrent Pharma’s proposal to buy stake in JB Chemicals
Fair trade regulator CCI on Tuesday cleared Torrent Pharmaceuticals Ltd’s proposed acquisition of a stake in JB Chemicals and Pharmaceuticals, subject to voluntary modifications offered by the companies. The...
Natco Pharma to acquire significant stake in S African firm Adcock Ingram
India’s Natco Pharma will acquire significant stakes in 135-year-old South African pharmaceutical giant Adcock Ingram. The R 4.2-billion deal will see Adcock Ingram becoming a privately-held entity co-owned by...
Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push
Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing competition from generic...
Life sciences companies may turn to spin-offs to avoid sell-offs
Big Pharma continues its hunt for innovation, and with uncertain market and regulatory conditions, some life sciences companies may be feeling the pressure to make their M&A exit or need additional funding in this...
Genmab to buy Dutch cancer drugmaker Merus for $8 billion
Denmark’s Genmab has agreed to acquire Merus NV, a Nasdaq-listed Dutch biotech firm developing a head-and-neck cancer drug, for $8 billion in cash, the two companies said in a statement on Monday. The planned...
Lupin to acquire VISUfarma to broaden its portfolio of ophthalmic biz
Lupin announced its wholly owned subsidiary, Nanomi B.V. (Nanomi), has signed a definitive agreement for the acquisition of VISUfarma B.V. (VISUfarma), a portfolio company of global healthcare specialist investor GHO...
Pfizer to buy obesity startup Metsera for $4.9 billion
Pfizer Inc. will pay $4.9 billion for the obesity startup Metsera Inc. in a bid to catch up to rival drugmakers after failing to compete with its own weight-loss medications. The US drugmaker agreed to buy Metsera for...
Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera, FT reports
Pfizer is closing in on a potential $7.3 billion takeover of weight-loss drug developer Metsera, the Financial Times reported on Sunday, citing unidentified sources. The U.S. pharma firm will acquire New York City-based...
